• FAQ
  • Glossary
Fermer

FAQ

Pourquoi utilise-t-on des modèles animaux pour tester la sécurité d'un nouveau traitement ?
Pourquoi certaines maladies se prêtent-elles mieux que d'autres aux thérapies géniques et cellulaires ?
Que sont les ATMP et quelle est leur place dans la thérapie génique et cellulaire ?
Qu'est-ce que la thérapie génique et cellulaire ?

Voir toutes les FAQ

Fermer

Glossary

Adeno-associated virus (AAV)
Adenovirus
Adult stem cells
Agence européenne des médicaments (EMA)
Antibody
Antigen
Autorisation de fabrication
Autorisation de mise sur le marché
Autorisation de mise sur le marché conditionnelle
Autorisation de mise sur le marché sous circonstances exceptionnelles

Voir le glossaire complet

ATMP Engage PPI Directory

The PPI Directory contains patient and public involvement (PPI) resources for developers of cell and gene therapies, including toolkits, guidelines, advice, templates and case studies.

PPI Directory

PPI Themes
Research Field
Organisation Type
Development Stage
Audience
Country
Content Type
    Showing 5 of 174 results.
    Page 19 of 35
    2020

    Improving patient access to gene and cell therapies for rare diseases in Europe.

    Report for the Rare Impact project - improving access to ATMPs by European Organisation for Rare Diseases (EURORDIS)
    View this Resource

    Research Field

    • ATMP/Gene Therapy Development

    Organisation Type

    • Third Sector/Charity

    Development Stage

    • Service Delivery

    Audience

    • Researchers/Developers
    • Public/Patients
    • Charity Sector
    • Industry

    Country

    • Europe

    Content Type

    • Resource
    2016

    PREFER patient preferences project

    PREFER project by European Patient Forum (EPF)
    View this Resource

    Research Field

    • General

    Organisation Type

    • Third Sector/Charity

    Development Stage

    • Identifying/Prioritising Patient Need
    • Research and Clinical Development
    • Regulatory Approval
    • Health Technology Assessment
    • Service Delivery

    Audience

    • Researchers/Developers
    • Industry

    Country

    • Europe

    Content Type

    • Resource
    2020

    Health Outcomes Observatory (H2O) project

    Project by European Patient Forum (EPF)
    View this Resource

    Research Field

    • General
    • Biomedical Lab
    • Pharmaceutical

    Organisation Type

    • Third Sector/Charity

    Development Stage

    • Identifying/Prioritising Patient Need
    • Research and Clinical Development

    Audience

    • Researchers/Developers
    • Public/Patients
    • Charity Sector
    • Industry

    Country

    • Europe

    Content Type

    • Resource
    2014

    Revised framework for interaction between the European Medicines Agency and patients and consumers and their organisations

    Generic PPI framework by the European Medicines Agency
    Visit this Resource

    Research Field

    • Other

    Organisation Type

    • Regulatory Body

    Development Stage

    • Regulatory Approval

    Audience

    • Researchers/Developers
    • Public/Patients

    Country

    • Europe

    Content Type

    • Resource
    2020

    EMA Regulatory Science to 2025 - strategic reflection

    Report reflecting on the EMA's regulatory framework by the European Medicines Agency
    View this Resource

    Research Field

    • Other

    Organisation Type

    • Regulatory Body

    Development Stage

    • Regulatory Approval

    Audience

    • Researchers/Developers
    • Public/Patients

    Country

    • Europe

    Content Type

    • Resource
    Retour en haut de page